Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Hospitals & Diagnostics
    • Fortis, RHT extend...

    Fortis, RHT extend last date for completing acquisition

    Written by Ruby Khatun Khatun Published On 2018-08-27T11:53:00+05:30  |  Updated On 27 Aug 2018 11:53 AM IST
    Fortis, RHT extend last date for completing acquisition

    New Delhi: Fortis Healthcare Ltd and RHT Health Trust have agreed to extend the last date for the acquisition of an entire portfolio of assets of the Singapore listed entity.


    "FHL and RHT have agreed to amend the Long Stop Date in the definitive agreement for the fulfillment of conditions precedent from September 30, 2018, to December 31, 2018, or such other date as may be mutually agreed between the parties in writing," Fortis said in a filing to BSE today.


    FHL is in process of raising funds via primary infusion which will enable it to acquire the RHT assets. The fund raise process is underway and awaiting regulatory approvals, it added.


    Another principal amendment agreed upon by both parties is that the consideration Fortis pays will be computed on the Rs: SGD closing offer rate one business day prior to the completion date, Fortis Healthcare said.


    However, if the closing offer rate is lower than the closing offer rate on September 30, 2018, then the reference rate for computing the consideration shall be that of September 30, 2018, it added.


    Besides, they have agreed that Fortis would compensate RHT for all the reasonable costs that may be incurred by RHT for obtaining services from legal advisers, independent financial adviser, tax advisers, valuers and reporting accountants solely resulting from the extension of the Long Stop Date, Fortis Healthcare said.


    "Fortis believes that the proposed transaction will potentially enhance value for all its stakeholders," it added.


    With the unwinding of the current structure, it would also make it easier for investors and other stakeholders to better understand the company's business and financial performance, it added.


    Upon completion of the securities acquisition, the service fees that Fortis was paying will be completely eliminated thereby improving significantly its operating profitability such as EBITDA and cash flows, Fortis Healthcare said.


    On February 13, Fortis Healthcare had said that it has entered into definitive agreements RHT to acquire an entire portfolio of assets of the Singapore-listed entity for an enterprise value of Rs 4,650 crore.

    AcquisitionEBITDAFHLfinancial adviserFortisFortis Healthcare LtdRHTRHT Health Trusttax advisersvaluers
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok